| Title | Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey. |
|-------|--------------------------------------------------------------------------------------------------|
| Author(s) | Lim, S; Lam, CLD; Muttalif, AR; Yunus, F; Wongtim, S; Le Thi Tuyet, L; Shetty, V; Chu, R; Zheng, J; Perng, DW; de Guia, T |
| Citation | Asia Pacific Family Medicine, 2014, v. 14 n. 1, p. 4 |
| Issued Date | 2014 |
| URL | http://hdl.handle.net/10722/217177 |
| Rights | This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. |
Impact of chronic obstructive pulmonary disease (COPD) in the Asia-Pacific region: the EPIC Asia population-based survey

Sam Lim, David Chi-Leung Lam, Abdul Razak Muttalif, Faisal Yunus, Sormkit Wongtim, Le Thi Tuyet Lan, Vikram Shetty, Romeo Chu, Jinping Zheng, Diahn-Warng Perng and Teresita de Guia

Abstract

Background: Chronic obstructive pulmonary disease (COPD) is a clinical syndrome encompassing a group of chronic, progressive, and debilitating respiratory conditions, that are characterized by incompletely reversible airflow limitation. Within the Asia-Pacific region, prevalence estimates have been derived using various protocols and study methods, and there is little data on the impact of COPD exacerbations. This study aimed to provide a comprehensive picture of the current prevalence and burden of COPD in this region.

Methods: A population-based survey was conducted in nine Asia-Pacific territories between 01 February 2012 and 16 May 2012. Overall, 112,330 households were screened to identify eligible subjects (aged ≥40 years, with a physician diagnosis of COPD, chronic bronchitis or emphysema, or with identifiable symptoms of chronic bronchitis). Out of a sample of 69,279 individuals aged ≥40 years, 4,289 subjects with COPD were identified. Data were collected via face-to-face interviews or by fixed-line telephone, using a structured questionnaire. A total of 1,841 completed questionnaires were analyzed.

Results: The overall estimated COPD prevalence was 6.2%, with 19.1% of subjects having severe COPD. In the 12 months prior to the survey, nearly half of all subjects (46%) had experienced exacerbations, and 19% had been hospitalized as a result of their condition. When subjects were asked about the impact of their condition on employment, 23% said their condition kept them from working, and 42% felt that their condition limited their ability to work or their activities. Of those who reported taking prescription drugs, 20% did not know the name of the drugs they were taking. Prescription of oral corticosteroids was common, with 44% of subjects having used these during the previous year to manage their respiratory symptoms; in contrast, inhaler use was low (25%). Only 37% of subjects had taken a lung function test, and the majority (89%) of those tested did not know their test results.

Conclusions: Across the Asia-Pacific territories surveyed, the prevalence of COPD is high, indicating a substantial socioeconomic burden. Our findings suggest that there is considerable room for improvement in the management of COPD, and highlight a need to enhance patient and physician education in the region.

Keywords: Chronic obstructive pulmonary disease (COPD), Asia-Pacific, Population-based, Survey, Prevalence, Exacerbations, Impact, Quality of life (QoL)
Background
Chronic obstructive pulmonary disease (COPD) is a clinical syndrome that encompasses a group of chronic, progressive, and debilitating respiratory conditions, including emphysema and chronic bronchitis. COPD is the fourth leading cause of global mortality [1], and its prevalence is predicted to rise [2,3]. Despite the wealth of information regarding its causes, pathophysiology, and treatment options, the disease has historically been under-diagnosed and under-reported, especially within the Asia-Pacific region [1,4].

COPD is characterized by persistent, progressive airflow limitation, and is often accompanied by cough and increased sputum production [4]. Airflow limitation is associated with chronic inflammation in the lungs and is principally caused by long-term exposure to airborne irritants such as cigarette smoke. In the Asia-Pacific region, smoke from biomass fuels and industrial toxins are also known to be problematic risk factors [5-7]. The symptoms of COPD cause significant impairment of quality of life (QoL), including breathlessness, anxiety, and physical limitations, resulting in days of missed work [8].

COPD exacerbations, consisting of an acute worsening of the usual symptoms beyond normal day-to-day variation, can be particularly debilitating [4]. While some exacerbations may be relatively mild and go unreported [9], in severe cases they can be particularly debilitating, requiring weeks for full recovery [10]. Recent studies have indicated that there may be exacerbation-specific phenotypes [11,12], and that cough and sputum (chronic bronchitis) are associated with a greater exacerbation frequency [13,14].

Previous studies of the prevalence of COPD and its exacerbations in the Asia-Pacific have focused on individual countries or cities [15-19], or relied on mathematical modeling [20]. The Epidemiology and Impact of COPD (EPIC) Asia survey is the first population-based COPD survey to cover nine Asia-Pacific regions using the same study design and questionnaire. We collected data on COPD exacerbation and its indicators, such as cough and sputum, as these aspects of the disease have not been well documented in this region. We also considered measures of disease reporting, disease severity, and socioeconomic factors, along with treatment and management practices. The aim was to gain further insight regarding the current prevalence and burden of COPD in the Asia-Pacific region.

Methods
The EPIC survey was conducted between 01 February 2012 and 16 May 2012 in nine Asia-Pacific territories: China, Hong Kong, and Taiwan (North Asia), and Indonesia, Malaysia, the Philippines, Singapore, Thailand, and Vietnam (Southeast Asia). Household screening and subject selection were carried out by telephone or face-to-face interviews (Figure 1; Additional file 1: Table S1). A structured questionnaire was then administered to eligible subjects.

Households were screened by random sampling to reduce selection bias. Fixed-line random digit dialing (RDD) sampling was conducted in regions with a high coverage of fixed telephone lines. Numbers were chosen based on randomly selected blocks of numbers. In the remaining regions, area probability (cluster) sampling was conducted face-to-face (FF) in subjects’ homes. Areas were divided into primary sampling units, which were then randomly selected, and a block or building was chosen as a starting point.

Individuals who met the following criteria were eligible for inclusion in the survey: individuals aged ≥40 years, who reported either a physician diagnosis of the following: emphysema, chronic bronchitis, COPD, chronic obstructive airways disease, or chronic obstructive lung disease; or who met the following symptomatic definition of chronic bronchitis: production of phlegm or mucus from the lungs on all or most days for three consecutive months. As this was a community survey which did not include any research intervention, no ethical approval was required. Verbal consent was obtained from all subjects prior to participation in the survey. Participation was voluntary. Subjects were informed that their results may be published in scientific articles and their responses would be kept both anonymous and confidential.

The structured questionnaire used for data collection was based on those used in previous studies [21,22], with additional questions to capture information on exacerbations. This questionnaire was developed and implemented by Abt SRBI, Inc., on behalf of Takeda Pharmaceuticals. The same questionnaire and study design were utilized across all territories. Where necessary, the English language questionnaire was translated by a local translator to the local language and then reviewed by an independent translator with health research experience, as well as by local medical experts. During data collection, potential bias was mitigated by random sampling within households containing more than one eligible individual, multiple contact attempts to reduce contact failure, and quality control during interviews. The fieldwork teams received extensive training in all aspects of administering the questionnaire. Mock and pre-test interviews were used to confirm training standards and identify areas for modification.

Only eligible subjects who completed the study questionnaire were included in the analyses, which involved standard descriptive statistics. Disease prevalence was calculated as (100 x number of eligible subjects / number of individuals aged ≥40 years), and expressed as a percentage. Severe COPD was defined based on subjects’
recall of COPD classification by their physicians, according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria (GOLD grade III or IV), or using the following symptomatic definition: presence of the symptoms of chronic bronchitis, together with two or more exacerbations in the previous 12 months.

Results

Subject demographics

In the nine territories surveyed, a total of 112,330 households were screened, identifying 69,279 households with one or more individuals aged ≥40 years. Of the 69,279 individuals aged ≥40 years, 4,289 either had a physician’s diagnosis of COPD or met the symptomatic definition used in this survey. Of these 4,289 subjects with identified COPD, a total of 1,841 subjects completed the questionnaire (Figure 1). Almost half of the study population (44%) was between 45 and 60 years of age, and 56% were female. For country-specific figures, please refer to Additional file 1: Table S1. The mean interview duration was 41 minutes.

Estimated prevalence of COPD and related conditions

Based on the above criteria, the overall estimated prevalence of COPD was 6.2%, ranging from 4.5% in Indonesia to 9.5% in Taiwan (Table 1). The proportion of subjects with a physician diagnosis of COPD was 59%, with the remainder having the symptomatic definition. Physician diagnosis was higher in North Asia (72–93%) than in Southeast Asia (19–60%), with the exception of Vietnam (92%). Overall, 19.1% of the subjects met the definition of the severe phenotype used in this study, ranging from 12.5% in Malaysia to 37.5% in Vietnam (Table 1). The majority of subjects reported their COPD classification as GOLD stage I or II (34.1% and 37.9%, respectively), with only a minority reporting it as stage III (9.3%) or IV (2.1%) (Table 1). However, Southeast Asian countries had higher
Table 1 Subject demographics

| Self-reported characteristic | Overall | North Asia | Southeast Asia |
|------------------------------|---------|-----------|---------------|
|                              | EPIC Asia n = 1,841 | China n = 215 | Hong Kong n = 205 | Taiwan n = 207 | Indonesia n = 200 | Malaysia n = 200 | Philippines n = 200 | Singapore n = 200 | Thailand n = 214 | Vietnam n = 200 |
|------------------------------|---------|-----------|---------------|
| Age (years), %               |         |           |               |
| 40–44                        | 26      | 45        | 50            | 46            | 18              | 12              | 16             | 18              | 18              | 10              |
| 45–49                        | 19      | 28        | 28            | 30            | 14              | 14              | 15             | 10              | 14              | 18              |
| 50–54                        | 14      | 9         | 10            | 8             | 18              | 19              | 13             | 9               | 15              | 22              |
| 55–59                        | 11      | 4         | 4             | 3             | 13              | 16              | 14             | 13              | 15              | 15              |
| 60–64                        | 11      | 6         | 2             | 4             | 16              | 15              | 19             | 18              | 11              | 12              |
| 65+                          | 20      | 7         | 5             | 9             | 22              | 26              | 23             | 34              | 28              | 25              |
| Gender, %                    |         |           |               |
| Female                       | 56      | 40        | 47            | 60            | 49              | 67              | 63             | 59              | 64              | 60              |
| Work status, %               |         |           |               |
| Employed                     | 47      | 66        | 75            | 68            | 36              | 31              | 37             | 30              | 40              | 40              |
| Smoking, %                   |         |           |               |
| Never smoked on a regular basis | 58    | 45        | 53            | 60            | 53              | 69              | 56             | 68              | 55              | 64              |
| COPD prevalence, %           |         |           |               |
| EPIC Asia                    | 6.2     | 8.1       | 7.7           | 9.5           | 4.5             | 5.1             | 4.2            | 5.9             | 5.3             | 9.4             |
| Prevalence estimation models [20] | 6.3 | 6.5       | 3.5           | 5.4           | 5.6             | 4.7             | 3.5            | 6.3             | 5.0             | 6.7             |
| Severe symptomatic phenotype | 19.1    | 13.0      | 16.1          | 24.2          | 20.5            | 12.5            | 13.0           | 20.0            | 15.9            | 37.5            |
| Diagnosed vs symptomatic (Mean age of diagnosis/yr) | 59 vs 41 | 72 vs 28 | 90 vs 10 | 93 vs 7 | 60 vs 40 | 33 vs 67 | 40 vs 60 | 19 vs 81 | 33 vs 67 | 92 vs 8 |
| MRC dyspnea score (mean) [23] | 2.3      | 1.8       | 2.2           | 2.2           | 2.6             | 2.4             | 2.6            | 2.4             | 2.1             | 2.5             |
| GOLD stage of severity [4], % |         |           |               |
| Stage I – Mild               | 34.1    | 44.7      | 52.2          | 44.0          | 28.0            | 26.5            | 30.5           | 27.0            | 20.6            | 32.5            |
| Stage II – Moderate          | 37.9    | 32.1      | 32.2          | 34.8          | 44.0            | 34.0            | 35.5           | 48.5            | 36.0            | 44.5            |
| Stage III – Severe           | 9.3     | 5.6       | 2.9           | 4.8           | 16.5            | 9.5             | 5.0            | 13.5            | 9.3             | 17.5            |
| Stage IV – Very severe       | 2.1     | 0.9       | 1.0           | 0.5           | <0.5            | 2.5             | 4.0            | 4.0             | 4.2             | 2.0             |
| Not diagnosed/not told       | 11.2    | 14.4      | 10.2          | 13.5          | 6.5             | 14.5            | 6.5            | 4.5             | 28.0            | 1.5             |
| Don’t know                   | 5.3     | 2.3       | 1.0           | 2.4           | 5.0             | 13.0            | 18.5           | 2.5             | 1.9             | 2.0             |
| Other frequent health conditions, % |         |           |               |
| None                         | 45      | 61        | 61            | 63            | 47              | 47              | 29             | 39              | 18              | 40              |
| Nasal allergies              | 13      | 18        | 20            | 15            | 2               | 3               | 11             | 2               | 32              | 14              |
| Arthritis                    | 11      | 7         | 11            | 6             | 5               | 6               | 19             | 4               | 13              | 24              |
| Asthma                       | 19      | 1         | 5             | 2             | 17              | 21              | 40             | 33              | 48              | 7               |
| Diabetes                     | 10      | 5         | 4             | 4             | 8               | 18              | 10             | 24              | 17              | 4               |
| Hypertension                 | 21      | 9         | 8             | 5             | 13              | 23              | 23             | 36              | 42              | 28              |
| Heart disease                | 5       | <1        | 2             | 1             | 7               | 11              | 6              | 5               | 8               | 5               |
| General health status, %     |         |           |               |
| Excellent                    | 2       | 2         | <1            | 1             | 9               | <1              | <1             | <1              | <1              | <1              |
| Very good                    | 3       | 9         | 2             | 5             | 2               | 6               | 3              | 2               | <1              | <1              |
| Good                         | 17      | 17        | 14            | 12            | 13              | 25              | 20             | 19              | 26              | 6               |
percentages of subjects with severe or very severe disease. The mean MRC dyspnea score [23] was 2.3.

Health status and disease symptoms
There was a clear North/Southeast division in reported health status (Table 1). The proportion of subjects who report that their health was ‘poor’ or worse ranged from 11–14% in North Asia to 19–59% in Southeast Asia. Similarly, the proportion who considered their general health to be ‘fair’ varied from 22% in Malaysia to 70% in Hong Kong.

Overall, a substantial proportion of subjects (33–53%) reported symptoms typical of COPD at least twice a week during their worst month in the previous 12 months (Additional file 2: Figure S1). Overall, 34% of the subjects reported that physical exertion instigated their COPD symptoms (Additional file 2: Figure S1D).

Exacerbations and unplanned healthcare utilization
Almost half (46%) of all subjects reported experiencing exacerbations in the 12 months prior to the survey (Figure 2A). The frequency and seasonal variation of reported exacerbations is shown in Figure 2B and C. The median number of exacerbations reported was 3, with all territories falling within the range of 2–4 (Figure 2B). Exacerbations occurred more frequently between October and January (Figure 2C). For the North Asian territories and the Philippines, an increase in exacerbations was also seen in the months from February to April. Subjects reported worsening of their disease symptoms during exacerbations, with over half of the subjects reporting coughing up phlegm or sputum, or coughing during the day (Additional file 2: Figure S2).

Overall, a sizable proportion of study subjects reported visiting a hospital emergency room (26%), or making other unscheduled visits to a doctor or clinic (32%) in the previous 12 months, as a result of their condition (Figure 3A). China (46%), Hong Kong (59%), and Taiwan (59%) recorded the highest percentages of unscheduled doctor or clinic visits (Figure 3A). Overall, 19% of study subjects reported being hospitalized in the previous 12 months as a result of their condition (Figure 3B).

Impact of disease on employment and daily activities
Less than half (47%) of all subjects were employed (either full- or part-time), with the employment rate in North Asia being higher (66–75%) than in Southeast Asia (30–40%) (Figure 4A). A substantial proportion of subjects (23%) reported that their condition kept them from working (Figure 4B), particularly in Indonesia (44%) and in the Philippines (51%). In addition, 42% felt that their condition limited the kind or amount of work they could do, or limited their activities (Figure 4B). Subjects were also asked to estimate their levels of productivity on a typical day, and on a day when symptoms were at their worst. Overall, average estimated productivity was 72% on a typical day, falling to 45% when the condition was at its worst (Figure 4C).

The impact of disease symptoms on daily activities was also explored (Additional file 2: Figure S3). Notably, 39% reported that their condition limited normal physical activities, such as walking. A substantial proportion of subjects (27–49%) said that their respiratory symptoms placed restrictions on a range of daily activities, including sleep, household chores, social or recreational activities, or affected their sex life (Additional file 2: Figure S3, A–C).

Disease management
Most subjects reported seeing either a specialist (44%) or general practitioner (34%) for their condition. However, only 37% of study subjects reported that they had been given a lung function test. Of those tested, 89% did not know their test results (either forced expiratory volume in the first second [FEV1] value, or percent predicted FEV1). Of those who reported taking prescription drugs, 20% did not know the name of the drugs they were taking. When subjects were asked to describe the delivery format of their medication, 57% stated pill/capsule, 13% stated inhaler with spacer, and 12% stated inhaler without spacer (Figure 5). In addition, 44% of the subjects reported the use of oral corticosteroids to manage their symptoms during the previous 12 months (Figure 6). Overall, 35% of the subjects had taken antibiotics for respiratory infections during the previous 12 months, and 13% had received an influenza vaccination.

Perceptions of disease and attitudes toward physician advice
Subjects were asked questions related to their perception of their condition. More than one-third (35%) felt that
there were no truly effective treatments for COPD (Additional file 2: Figure S4A). The majority of subjects (76%) believed that smoking was the cause of their condition, and 70% felt that their condition worsened with increasing age, regardless of treatment (Additional file 2: Figure S4B). However, most subjects felt that with appropriate treatments, progressive increase in breathlessness could be slowed (86%) or they could lead a full and active life (84%) (Additional file 2: Figure S4C).

When asked about the extent to which their doctor’s advice regarding treatment and management helped improve their condition, 43% said ‘a lot’ (Additional file 2: Figure S5A). When subjects were asked about the extent to which their doctor’s advice regarding lifestyle and habits helped, a similar percentage of subjects (39%) said ‘a lot’ (Additional file 2: Figure S5B).

Discussion

The EPIC Asia survey was a multi-country, cross-sectional, population-based study that examined the prevalence and burden of COPD in the participating Asian territories, from the perspective of individuals who were diagnosed with the disease or who reported symptoms of the disease. This approach contrasts with previous studies in Asia, which have tended to focus on individual countries or areas within countries [15-19].

Using data obtained from the nine Asian territories in this population-based survey, the average prevalence of
COPD was estimated at 6.2%. Almost one-fifth of the identified subjects were categorized as having severe or very severe COPD, based on recalled disease classification by a physician, or on their reported symptoms of chronic bronchitis and frequent exacerbations. The prevalence of COPD estimated in this study is similar to that reported by Tan et al. who used a mathematical model to estimate the prevalence of COPD in this region (6.3%) [20]. Similarly, it is consistent with the pooled global prevalence (7.6%) obtained from a meta-analysis of 37 population-based COPD studies using different definitions of COPD including spirometric criteria, patient-reported diagnoses, physician diagnoses, etc. [24]. However, a population-based study which employed spirometric measurements to estimate the prevalence of COPD in 12 countries (the BOLD study), revealed higher COPD estimates (worldwide 10.1%, participating Asian countries 11.4–13.9%) compared with our study. The BOLD study also showed higher levels of severe COPD in the participating Asian countries (1.7–5.0%) [25]. Given that identification of COPD in our study was based on subject-reported physician diagnoses and subjects’ perception of their condition and symptoms, it is likely that the actual prevalence of COPD in the participating Asian territories is higher than was estimated.

The results of this survey may not be directly comparable to those of other COPD studies, due to differences in measurement methodology or study population. Nevertheless, our findings and those of other studies in Asia and elsewhere [15,16,22,24-26] indicate that COPD represents a substantial socioeconomic burden in this region and worldwide. In this study, a large proportion of subjects reported that their condition restricted their work or activities (42%), or kept them from working altogether (23%). Another noteworthy finding is the high rate of hospitalization reported; almost a fifth (19%) of subjects said they had been hospitalized as a result of their condition in the previous year. Unplanned healthcare utilization was also common, with a substantial proportion of subjects visiting a hospital emergency room (26%), or making unscheduled doctor or clinic visits (32%) in the year prior to the survey. In the BOLD study, patients with COPD reported poorer health status than those without COPD; the degree of impairment was greater with increasing COPD severity. Furthermore, patients regarded severe COPD to have a greater negative impact on their health status than diabetes and cardiovascular [26].

Other findings from our study suggest an urgent need for improved clinical management in this region, as well
as for better patient education. For instance, a relatively low proportion of subjects had undergone lung function tests (37%), and the majority of those tested did not know their test results (either FEV\textsubscript{1} value or percent predicted FEV\textsubscript{1}). A fifth of those who reported taking prescription drugs did not know the name of the drugs they were taking. From the perspective of recommended clinical practice, oral corticosteroids appear to be overprescribed, whereas the use of inhalers is low.

Most studies on COPD are conducted on a selected population who are smokers. Although smoking history is important for COPD diagnosis, environmental pollutants, such as industrial toxins and smoke from biomass fuels, are also highly relevant risk factors, particularly in the Asia-Pacific region [5-7]. Further, smoking status tends to be under-reported [27]. Inclusion of both self-reported smokers and non-smokers in this survey allows the capture of important information on subjects who are smokers but do not accurately report their smoking status, or those whose COPD may be caused by environmental pollutants.

Our findings need to be interpreted within the limitations of the study. Firstly, identification of COPD in subjects was based on subject-reported physician diagnoses, where available, or on the presence of self-reported

![Figure 4 Impact of disease on employment and work productivity. (A) Employment status of study subjects. (B) Proportion of subjects who reported that their condition kept them from working, limited the kind or amount of work they could do, or limited their activities. (C) Subjects’ estimated level of productivity on a typical day, and on a day when symptoms are at their worst. Upper row of n values: subjects who answered the question regarding productivity on a typical day; lower row of n values: subjects who answered the question regarding their worst day.](image)
Use of oral corticosteroids. All study subjects (upper row of n values) were asked if they had been told to use oral steroids to manage their respiratory symptoms in the past 12 months. Those who had been prescribed steroids (lower row of n values) were asked if they had been told to take the steroids for three days or longer.

Figure 5 Delivery format of prescribed medication. Subjects who reported taking a prescription drug were asked about the delivery format of their medication. Numbers below the bars indicate the total number of valid answers for this question, for the corresponding territory. Results are shown only for subjects who were able to report the delivery format of their medication.

Figure 6 Use of oral corticosteroids. All study subjects (upper row of n values) were asked if they had been told to use oral steroids to manage their respiratory symptoms in the past 12 months. Those who had been prescribed steroids (lower row of n values) were asked if they had been told to take the steroids for three days or longer.
respiratory symptoms. Similarly, classification of disease severity was based either on subjects’ recall of GOLD classification by a physician, where available, or on their recall of symptomatic criteria. As this was a community survey, subjects were screened based on their reported information; there was no confirmation of diagnoses via subject diaries or spirometric measurements. Consequently, there is potential underdiagnosis, as well as misclassification of COPD and disease severity due to recall bias and subjects’ misperception of their disease condition or symptoms. This may lead to less reliable prevalence estimates. Secondly, subjects who were interviewed via the telephone were likely to have higher social economic status than those who had face-to-face interview. This could result in a selection bias. Potential bias was minimized by conducting random sampling both in regions with high coverage of fixed telephone lines, as well as in those areas without telephone access.

Another limitation of this study is the low response rate which could have introduced the potential for response bias. Subjects were unable to participate in the survey due to various reasons which included ineligible or refusal to participate, contact failure, and inability to complete survey. Hence, it was not possible to collect demographics information from the non-respondents to assess if response bias exists. Nonetheless, steps were taken to mitigate potential bias. Households were randomly selected by RDD or area probability sampling. In households where more than 1 subject was eligible, random sampling was performed to select only 1 subject. In addition, multiple contact attempts were made to reduce contact failure. Another limitation of this study is that the sample size of each country may not be large enough to allow meaningful conclusions to be drawn about each country. Nevertheless, the study enrolled a near uniform number of subjects in each country that minimized the likelihood that the overall prevalence would be affected by unbalanced sample size in any country.

**Conclusions**

The results of the EPIC Asia population-based survey suggest a high prevalence of COPD in the participating Asia-Pacific territories, and indicate a substantial socioeconomic burden of the disease in this region. Individuals with the disease reported substantial limitations in their daily activities and loss in work productivity. These findings highlight the need to enhance patient and physician education, and improve the management of COPD in this region.

**Additional files**

**Additional file 1: Table S1.** Sampling frame for the EPIC Asia survey, by country. Subjects from each of the nine participating territories were sampled either by telephone, using random digit dialing (RDD), or face-to-face (FF) interviews in their local language, to identify individuals who had either received a physician diagnosis of COPD or who met the symptomatic criteria used (see Methods).

**Additional file 2: Figure S1.** Frequency of COPD symptoms experienced over the previous 12 months. Proportion of subjects who experienced the following COPD symptoms at least twice per week in their worst month over this period: (A) being awakened at night either by coughing or shortness of breath, (B) coughing or shortness of breath during the day, (C) coughing up phlegm or wheezing, or (D) tightness of the chest or coughing, wheezing, shortness of breath, or chest tightness due to physical exertion. **Figure S2.** Exacerbation symptoms. The types of symptoms reported to be elevated during exacerbation episodes, as reported by subjects who experienced exacerbations in the 12 months prior to the survey. **Figure S3.** Restriction of daily activities by COPD symptoms. The proportion of subjects who reported that their symptoms impose ‘some’ limitation or limit their activities ‘a lot’ with respect to: (A) sports and recreation and normal activities such as walking, (B) social activities or sleeping, and (C) housekeeping chores or their sex life.

**Figure S4.** Subjects’ attitudes to COPD. The proportion of subjects who ‘agreed’ or ‘agreed strongly’ that: (A) there are no truly effective treatments for their condition; (B) smoking is the cause of their condition, and that their condition tends to get worse as they get older; (C) with proper treatment, a progressive increase in breathlessness can be slowed and that most people with the condition can live a full and active life. **Figure S5.** Subjects’ attitudes to their physician’s advice. The proportion of subjects who reported that their physician’s advice on (A) management and treatment, or (B) modification of lifestyle and habits, improved their ability to manage their respiratory symptoms to the following degrees: ‘Not at all’, ‘Only a little’, ‘Some’, or ‘A lot’. Results are shown only for subjects who provided valid answers to the questions.

**Competing interests**

SL, DCLL, SW, LTTL, JPZ, and TG have received consulting fees from Takeda Pharmaceuticals GmbH. SL has received speaker fees from GlaxoSmithKline (GSK) and AstraZeneca. TG has received research grants, lecture fees or travel grants from GSK, United Laboratories (UNILAB), AstraZeneca, Boehringer Ingelheim, Sanofi-Aventis, Getz Pharma, Nycomed-Takeda, Pfizer, and Novartis, and has served on Advisory Boards for GSK, Novartis, Nycomed-Takeda, Boehringer Ingelheim, and UNILAB. LTTL has served on Advisory Boards for GSK, AstraZeneca, Novartis, and Boehringer Ingelheim, and has received research grants from Astra Zeneca, MSD, and GSK. She has received speaker fees and travel grants from GSK, Astra Zeneca, Novartis, and Boehringer Ingelheim. JPZ has received lecture fees from GSK, AstraZeneca, Boehringer Ingelheim, Nycomed-Takeda, and Novartis, and has served on Advisory Boards for AstraZeneca, GSK, Novartis, Nycomed-Takeda, and Boehringer Ingelheim. VS and RC are both ex-employees of Takeda Pharmaceuticals. They were employees of Takeda Pharmaceuticals during the conduct of this study. All other authors declare that they have no competing financial interests.

**Authors’ contributions**

All authors contributed equally to the analysis of the data and the development of the manuscript. All authors have read and approved the final manuscript.

**Acknowledgements**

The study was funded by Takeda Pharmaceuticals International GmbH. Additional medical writing support was provided by Caroline Loder and Michael Kieran at Synergy Vision (London), and by ResearchTools Clinical Solutions Pte. Ltd (Singapore); this support was funded by Takeda.

**Author details**

1Duke-NUS Graduate School of Medicine, Singapore, Singapore. 2Department of Medicine, University of Hong Kong, Pokfulam, Hong Kong. 3Institute of Respiratory Medicine, Kuala Lumpur, Malaysia. 4Department of Pulmonology and Respiratory Medicine, Universitas Indonesia (FMUI), Jakarta, Indonesia. 5Department of Internal Medicine, Chulalongkorn University, Bangkok, Thailand. 6Respiratory Care Center, University Medical Center, Ho Chi Minh City, Vietnam. 7Takeda Pharmaceuticals (Asia-Pacific) Pte. Ltd, Singapore, Singapore. 8State Key Lab of Respiratory Disease, National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Disease.
First Affiliated Hospital of Guangzhou Medical University, Guangzhou, People’s Republic of China. bChest Department, Taipei Veterans General Hospital and School of Medicine, National Yang Ming University, Taipei, Taiwan. cDivision of Pulmonary and Critical Care Medicine, Philippine Heart Center, Quezon City, Philippines.

Received: 22 January 2014 Accepted: 18 March 2015
Published online: 23 April 2015

References
1. World Health Organization: Global burden of disease 2004 update. Available from: http://www.who.int/healthinfo/global_burden_disease.
2. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3:e442.
3. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990–2020: Global Burden of Disease Study. Lancet. 1997;349:1498–504.
4. The Global Initiative for Chronic Obstructive Lung Disease (GOLD): The Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Revised 2013. Available from: http://www.goldcopd.org.
5. Boschetto P, Quintavalle S, Micotto D, Lo Cascio N, Zeni E, Mapp CE. Chronic obstructive pulmonary disease (COPD) and occupational exposure. J Occup Med Toxicol. 2006;1:11.
6. Hu G, Zhou Y, Tian J, Yao W, Li J, Li B, et al. Risk of COPD from exposure to biomass smoke: a meta-analysis. Chest. 2010;138:20–31.
7. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet. 2009;374:733–43.
8. Kessler R, Stahl E, Vogelmeier C, Haughney J, Trudeau E, Lofdahl CG, et al. Patient understanding, detection, and experience of COPD exacerbations: an observational, interview-based study. Chest. 2006;130:133–42.
9. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1998;157:1418–22.
10. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2000;161:1608–13.
11. Hurst JR, Vestbo J, Anzueto A, Locantore N, Mulleroa H, Tal-Singer R, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128–38.
12. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE). Eur Respir J. 2008;31:89–73.
13. Burge P, Nesme-Meyer P, Chanez P, Caillaud D, Carre P, Perez T, et al. Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest. 2009;135:975–82.
14. de Oca MM, Halbert RJ, Lopez MV, Perez-Padilla R, Talanz C, Moreno D, et al. The chronic bronchitis phenotype in subjects with and without COPD: the PLATINO study. Eur Respir J. 2012;40:28–36.
15. Fukushima Y, Nishimura M, Ichinose M, Adachi M, Nagai A, Kuriyama T, et al. COPD in Japan: the Nippon COPD Epidemiology study. Respirology. 2004;9:458–65.
16. Idolor LF, Tsdeeg, Francisco NA, Roa CC, Ayuyao FG, Tady CZ, Tan DT, et al. Burden of obstructive lung disease in a rural setting in the Philippines. Respirology. 2011;16:1111–8.
17. Maranetra KN, Chuaychoo B, Jeevomrutiu W, Chiankul N, Nana A, Lertakyamanee J, et al. The prevalence and incidence of COPD among urban older persons of Bangkok Metropolis. J Med Assoc Thai. 2002;85:1147–55.
18. Yoo KH, Kim YS, Sheen SS, Park JH, Hwang YI, Kim SH, et al. Prevalence of chronic obstructive pulmonary disease in Korea: the fourth Korean National Health and Nutrition Examination Survey. 2008. Respirology. 2011;16:659–65.
19. Zhong N, Wang C, Yao W, Chen P, Kang J, Huang S, et al. Prevalence of chronic obstructive pulmonary disease in China: a large, population-based survey. Am J Respir Crit Care Med. 2007;176:573–60.
20. Tan WC, Seale JP, Charoenrattanakul S, de Guia T, Ip M, Mahayiddin A, et al. COPD prevalence in 12 Asia-Pacific countries and regions: projections based on the COPD prevalence estimation model. Respirology. 2003;8:192–8.
21. Halpern MT, Stanford RH, Borker R. The burden of COPD in the USA: results from the Confronting COPD survey. Respir Med. 2003;97(Suppl C):S81–9.